new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp A Corporation A Subsidiary Of Merck x26 Co Inc
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212
Merck Sharp x26 Dohme Corp Institute De Recherche Pierre Fabre

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors




Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12015008650503/26/15 Mono- and di-peg il-10 production; and uses
22015001159001/08/15 Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
32012025303210/04/12 Novel cationic lipids with short lipid chains for oligonucleotide delivery
42012020281908/09/12 Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
52016011391004/28/16  new patent  Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
62016011400004/28/16  new patent  Co-agonists of the glucagon and glp-1 receptors
72016010683504/21/16 Combination therapies for cancer
82016010804804/21/16 Imidazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
92016010805904/21/16 Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
102016010207304/14/16 2-hydroxymethyl-substituted orexin receptor antagonists
112016009685804/07/16 Selective glycosidase inhibitors and uses thereof
122016008200503/24/16 Process of making and using pharmaceutical formulations of antineoplastic agents
132016008376503/24/16 Method for preparing antibodies having improved properties
142016008483903/24/16 Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
152016008484803/24/16 Assay for determining endogenous levels of analyte in vivo
162016007450203/17/16 Recombinant subunit dengue virus vaccine
172016007564503/17/16 Amidation process
182016007565003/17/16 Crystalline polymorphic forms of an antidiabetic compound
192016007565603/17/16 Quinoline amide m1 receptor positive allosteric modulators
202016007568403/17/16 Alpha 7 nicotinic acetylcholine receptor modulators and uses thereof-iii
212016007572403/17/16 Cetp inhibitors
222016006851003/10/16 Hydroxy-substituted orexin receptor antagonists
232016006851403/10/16 Halo and trifluoromethyl substituted orexin receptor antagonists
242016006853203/10/16 Novel compounds that are erk inhibitors
252016006859703/10/16 Fdf03 antibodies and uses thereof
262016006025503/03/16 Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
272016006025603/03/16 Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
282016006027203/03/16 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
292016005325102/25/16 Immobilized ketoreductases and process for making and using immobilized ketoreductase
302016004552602/18/16 2'-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
312016004658102/18/16 Factor xia inhibitors
322016003981702/11/16 Triazolopyridyl compounds as aldosterone synthase inhibitors
332016004012402/11/16 Adapted lepidopteran insect cells for the production of recombinant proteins
342016004020102/11/16 Biocatalytic transamination process
352016004025202/11/16 Methods and compositions for treating cancer
362016004377402/11/16 C6-azaspiro iminothiadiazine dioxides as bace inhibitors, compositions, and their use
372016003188202/04/16 Imidazopyridyl compounds as aldosterone synthase inhibitors
382016002409101/28/16 Inhibitors of the renal outer medullary potassium channel
392016002410001/28/16 Process for preparing chiral dipeptidyl peptidase-iv inhibitors
402016001692101/21/16 S-imino-s-oxo-iminothiazine compounds as bace inhibitors, compositions, and their use
412016001692301/21/16 S-imino-s-oxo-iminothiadiazine compounds as bace inhibitors, compositions, and their use
422016001693501/21/16 2-pyridyloxy-4-ether orexin receptor antagonists
432016001694701/21/16 Substituted pyridizinone derivatives as pde10 inhibitors
442016001697501/21/16 C2-azaspiro iminothiazine dioxides as bace inhibitors, compositions, and their use
452016001703601/21/16 Cell line 3m
462016000836101/14/16 Compositions and methods for treating cancer
472016000968101/14/16 Compounds inhibiting leucine-rich repeat kinase enzyme activity
482016000968201/14/16 Compounds inhibiting leucine-rich repeat kinase enzyme activity
492016000968901/14/16 Compounds inhibiting leucine-rich repeat kinase enzyme activity
502016000969601/14/16 Compounds inhibiting leucine-rich repeat kinase enzyme activity
512016000072101/07/16 Gastro-retentive formulations
522016000092101/07/16 Ceftolozane antibiotic compositions
532016000222401/07/16 Novel indole derivatives useful as anti-diabetic agents
542016000225501/07/16 Antidiabetic bicyclic compounds
552016000225901/07/16 Inhibitors of the renal outer medullary potassium channel
562015037479512/31/15 O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
572015037624912/31/15 Methods for increasing n-glycan occupancy and reducing production of hybrid n-glycans in pichia pastoris strains lacking alg3 expression
582015036824612/24/15 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
592015036824712/24/15 2,6,7 substituted purines as hdm2 inhibitors
602015036826512/24/15 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
612015036826912/24/15 Factor ixa inhibitors
622015036834412/24/15 Mdl-1 ligand
632015036868212/24/15 Immobilized transaminases and process for making and using immobilized transaminase
642015035979312/17/15 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
652015036109812/17/15 Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
662015036110112/17/15 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
672015035349812/10/15 Substituted isoquinolines as crth2 receptor modulators
682015035351612/10/15 Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as bace inhibitors, compositions, and their use
692015035353512/10/15 Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
702015035355212/10/15 Purine inhibitors of human phosphatidylinositol 3-kinase delta
712015035355312/10/15 2,6,7,8 substituted purines as hdm2 inhibitors
722015035356512/10/15 Btk inhibitors
732015035357012/10/15 Btk inhibitors
742015035518412/10/15 Antibodies that bind to human programmed death ligand 1 (pd-l1)
752015034293112/03/15 Spirocyclic cetp inhibitors
762015034315312/03/15 Dual chamber mixing syringes and methods of using same
772015034315712/03/15 Medication injector with near-empty alert
782015034448712/03/15 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
792015034450012/03/15 C2,c6 oxacyclic-fused thiazine dioxide compounds as bace inhibitors, compositions, and their use
802015033564811/26/15 Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases
812015033694611/26/15 Novel 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment
822015033694811/26/15 Isotopically labeled biaryl urea compounds
832015033699111/26/15 Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment
842015033701311/26/15 Novel antibacterial agents for the treatment of gram positive infections
852015033727411/26/15 Pmt2-, och1-, pmt5- mutant cells
862015032952111/19/15 Process for making reverse transcriptase inhibitors
872015032953111/19/15 Amino-pyrimidine-containing spleen tyrosine kinase (syk) inhibitors
882015032953911/19/15 4-pyridinonetriazine derivatives as hiv integrase inhibitors
892015032954811/19/15 Substituted pyrrolopyrimidines as hdm2 inhibitors
902015032955711/19/15 Inhibitors of the renal outer medullary potassium channel
912015032956211/19/15 Factor ixa inhibitors
922015032961211/19/15 Process for purifying insulin and analogues thereof
932015032962811/19/15 Liquid formulations for an anti-tnf alpha antibody
942015032963211/19/15 Solution formulations of engineered anti-il-23p19 antibodies
952015032072411/12/15 Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
962015032073311/12/15 Indazole compounds as aldosterone synthase inhibitors
972015032086011/12/15 Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
982015032203911/12/15 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
992015032204011/12/15 3-ester-4 substituted orexin receptor antagonists
1002015032204111/12/15 2-pyridyloxy-4-nitrile-4-substituted orexin receptor antagonists
1012015032205611/12/15 Factor ixa inhibitors
1022015032207411/12/15 4-fluoropiperidine orexin receptor antagonists
1032015032251911/12/15 Biomarkers for psoriasis treatment response
1042015031522111/05/15 Nucleoside kinase bypass compositions and methods
1052015031392611/05/15 Syn3 compositions and methods
1062015031514111/05/15 Thrombin inhibitors
1072015031522111/05/15 Nucleoside kinase bypass compositions and methods
1082015031522611/05/15 Disulfide masked prodrug compositions and methods
1092015030609110/29/15 Aldosterone synthase inhibitors
1102015030746410/29/15 Therapeutic thiazolidinone compounds
1112015030746510/29/15 Iminothiadiazine dioxide compounds as bace inhibitors, compositions and their use
1122015030747910/29/15 Cyclobutyl benzimidazoles as pde 10 inhibitors
1132015030748810/29/15 Cyclopropyl imidazopyridine pde10 inhibitors
1142015030748910/29/15 Pyrimidine pde10 inhibitors
1152015030753310/29/15 Spirocyclic sulfones as gamma secretase inhibitors
1162015030758010/29/15 Oxyntomodulin analogs
1172015030759110/29/15 On-column refolding and purifying of lipoproteins
1182015030760610/29/15 Lyophilized spherical pellets of anti-il-23 antibodies
1192015030785010/29/15 Conditional replicating viral vectors
1202015029919810/22/15 Inhibitors of the renal outer medullary potassium channel
1212015029964810/22/15 Improved cultivation media and process for improved protein production by pichia strains
1222015029756610/22/15 Rorgammat inhibitors
1232015029912210/22/15 Glycosidase inhibitors and uses thereof
1242015029912510/22/15 Prodrug bipyridylaminopyridines as syk inhibitors
1252015029916710/22/15 Regioselective n-2 arylation of indazoles
1262015029919810/22/15 Inhibitors of the renal outer medullary potassium channel
1272015029922410/22/15 Inhibitors of irak4 activity
1282015029922710/22/15 Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
1292015029924310/22/15 2'-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
1302015029964810/22/15 Improved cultivation media and process for improved protein production by pichia strains
1312015029969010/22/15 Engineered lower eukaryotic host strains deficient in grr1 activity for recombinant protein
1322015029013510/15/15 Process for making agglomerates using acoustic mixing technology
1332015029032510/15/15 Liquid formulations for tnfr:fc fusion proteins
1342015029155810/15/15 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists
1352015029156110/15/15 Substituted pyridone derivatives as pde10 inhibitors
1362015029162010/15/15 Glycosidase inhibitors and uses thereof
1372015029168310/15/15 Modified apol1 polypeptides
1382015028436810/08/15 Secondary alcohol substituted triazoles as pde10 inhibitors
1392015028437610/08/15 Mineralocorticoid receptor antagonists
1402015028437910/08/15 Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions and their use
1412015028438110/08/15 Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors
1422015028438910/08/15 N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
1432015028441110/08/15 Novel azabenzimidazole hexahydrofuro[e,2-b]furan derivatives
1442015028475310/08/15 Process for the preparation of an intermediate for an orexin receptor antagonists
1452015027465610/01/15 Glycosidase inhibitors and uses thereof
1462015027466410/01/15 Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
1472015027467210/01/15 Substituted spiropiperidinyl compounds useful as gpr120 agonists
1482015027470810/01/15 Inhibitors of irak4 activity
1492015027471610/01/15 Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions and their use
1502015027473910/01/15 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
1512015027475510/01/15 Compound diversification using late stage functionalization
1522015027476710/01/15 4'-substituted nucleoside reverse transcriptase inhibitors
1532015027522210/01/15 Crz1 mutant fungal cells
1542015026571509/24/15 Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1552015026689509/24/15 Novel compounds that are erk inhibitors
1562015026689709/24/15 Hcv ns3 protease inhibitors
1572015025807409/17/15 Novel compounds that are erk inhibitors
1582015026073109/17/15 Antibodies, kit and detecting amyloid beta oligomers
1592015025075909/10/15 Composition for inhibition of cathepsin k
1602015025203309/10/15 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists
1612015025203409/10/15 Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
1622015025334109/10/15 Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
1632015024690209/03/15 Substitued benzofuran compounds and methods of use thereof for the treatment of viral diseases
1642015024691709/03/15 Inhibitors of hepatitis c virus replication
1652015023986608/27/15 Triazolyl derivatives as syk inhibitors
1662015023242808/20/15 Substituted phenyl-spleen tyrosine kinase (syk) inhibitors
1672015023244708/20/15 Crystalline form of a reverse transcriptase inhibitor
1682015022536508/13/15 Indoline compounds as aldosterone synthase inhibitors
1692015022540208/13/15 Treating diabetes with dipeptidyl peptidase-iv inhibitors
1702015021809608/06/15 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
1712015021809708/06/15 Glycosidase inhibitors and uses thereof
1722015021814708/06/15 Glycosidase inhibitors and uses thereof
1732015021814908/06/15 Novel benzimidazole tetrahydrofuran derivatives
1742015021816408/06/15 Substituted naphthyridinedione derivatives as hiv integrase inhibitors
1752015021816908/06/15 3-aminocycloalkyl compounds as rorgammat inhibitors and uses thereof
1762015020942407/30/15 Inactivated varicella zoster virus vaccines, methods of production, and uses thereof
1772015021068507/30/15 Novel azabenzimidazole tetrahydropyran derivatives
1782015021068707/30/15 N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
1792015020348707/23/15 Novel azabenzimidazole tetrahydrofuran derivatives
1802015020349607/23/15 Aliphatic spirolactam cgrp receptor antagonists
1812015020351207/23/15 Macrocyclic compounds as hiv integrase inhibitors
1822015019749007/16/15 Crystalline polymorphic forms of an antidiabetic compound
1832015019753107/16/15 Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
1842015019757007/16/15 Anti-ilt5 antibodies and ilt5-binding antibody fragments
1852015019777207/16/15 Mammalian expression vector puhab
1862015019040207/09/15 Solid dosage formulations of an orexin receptor antagonists
1872015019143407/09/15 3-cyclohexenyl and cyclohexyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
1882015019146107/09/15 Pyrazolyl derivatives as syk inhibitors
1892015019149507/09/15 Antidiabetic tricyclic compounds
1902015018250307/02/15 Mineralocorticoid receptor antagonists
1912015017553406/25/15 Alpha-7 nicotinic acetylcholine receptor modulators and uses therof-i
1922015017557506/25/15 Imidazolyl analogs as syk inhibitors
1932015017560906/25/15 Treating diabetes with dipeptidyl peptidase-iv inhibitors
1942015016648606/18/15 Substituted diazine and triazine spleen tyrosine kinease (syk) inhibitors
1952015016649006/18/15 Mineralocorticoid receptor antagonists
1962015016652006/18/15 Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
1972015015893506/11/15 Protective vaccine based on staphylococcus aureus sa2493 protein
1982015015099006/04/15 Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
1992015015212706/04/15 Permeable glycosidase inhibitors and uses thereof
2002015014733705/28/15 Crystalline anti-human il-23 antibodies
2012015014824605/28/15 Surface anchored light chain bait antibody display system
2022015014832705/28/15 Substituted pyridine spleen tyrosine kinase (syk) inhibitors
2032015013998605/21/15 Ilt3 binding molecules and uses therefor
2042015014142805/21/15 Trka kinase inhibitors, compositions and methods thereof
2052015014144405/21/15 N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
2062015012644305/07/15 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
2072015012649305/07/15 Bicyclic sulfone compounds for inhibition of rorgamma activity and the treatment of disease
2082015011939404/30/15 Insulin-like growth factor-1 receptor inhibitors
2092015011186604/23/15 Cyclic amine substituted heterocyclic cetp inhibitors
2102015011187704/23/15 Tetrahydronaphthyridine and related bicyclic compounds for inhibition of rorgamma activity and the treatment of disease
2112015011191404/23/15 Spirolactam cgrp receptor antagonists
2122015010445304/16/15 Fdf03 antibodies and uses thereof
2132015010446504/16/15 Il-19 as a biomarker of tslp treatment
2142015010531704/16/15 Glucose-responsive insulin conjugates
2152015010535404/16/15 Heterocyclic aspartyl protease inhibitors
2162015009989104/09/15 Novel crystalline forms of a dipeptidyl peptidase-iv inhibitors
2172015009971504/09/15 Formulations of acadesine
2182015009971904/09/15 Cathepsin cysteine protease inhibitors
2192015009972904/09/15 Inhibitors of the renal outer medullary potassium channel
2202015009977104/09/15 Pyridine cgrp receptor antagonists
2212015009339804/02/15 Methods and compositions for treating or preventing cancer
2222015008390603/26/15 Biomarkers for monitoring intervention therapies for diabetes
2232015008764103/26/15 Heterocyclic cgrp receptor antagonists
2242015008783203/26/15 Process for making beta 3 agonists and intermediates
2252015007899603/19/15 Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
2262015007903103/19/15 Use of pegylated il-10 to treat cancer
2272015008059803/19/15 Asymmetric synthesis for preparing fluoroleucine alkyl esters
2282015006419203/05/15 Mammalian cell surface antigens; related reagents
2292015005619102/26/15 Igf1 biomarker for igf1r inhibitor therapy
2302015005122702/19/15 Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
2312015005124802/19/15 Imidazolyl methyl piperidine t-type calcium channel antagonists
2322015004425002/12/15 Vaccines against clostridium difficile comprising recombinant toxins
2332015004534602/12/15 Selective glycosidase inhibitors and uses thereof
2342015004557502/12/15 Process for preparing fluoroleucine alkyl esters
2352015003849002/05/15 Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
2362015003849802/05/15 Thrombin inhibitors
2372015003850202/05/15 Isoxazolopyridine orexin receptor antagonists
2382015003870702/05/15 Process for making cgrp receptor antagonists
2392015003171301/29/15 Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
2402015003171601/29/15 Piperidinone carboxamide azaindane cgrp receptor antagonists
2412015003189101/29/15 Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
2422015002080601/22/15 Dry powder inhaler for delivering multipe agglomerate formulations
2432015002395201/22/15 Anti-addl monoclonal antibody and uses thereof
2442015002407101/22/15 Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
2452015002504601/22/15 Preparation and use of bicyclic himbacine derivatives as par-1 receptor antagonists
2462015001768601/15/15 Methods for reducing mannosyltransferase activity in lower eukaryotes
2472015001839901/15/15 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
2482015001056401/08/15 Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
2492015000460801/01/15 Monocyte-derived nucleic acids and related compositions and methods



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###